Stock 0QCV ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials AbbVie Inc. London S.E.

Equities

0QCV

US00287Y1091

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 11:30:00 2024-04-29 am EDT 		5-day change 1st Jan Change
159.8 USD -2.28% Intraday chart for AbbVie Inc. -5.62% +3.32%
05:26pm BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating MT
02:52pm Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 130,935 189,171 239,371 285,707 273,605 282,631 - -
Enterprise Value (EV) 1 157,739 266,778 306,225 339,749 320,176 335,733 329,334 320,274
P/E ratio 16.8 x 39.4 x 21 x 24.4 x 57 x 30.5 x 23.7 x 19.9 x
Yield 4.96% 4.52% 3.92% 3.53% 3.87% 3.88% 4.07% 4.25%
Capitalization / Revenue 3.94 x 4.13 x 4.27 x 4.92 x 5.04 x 5.13 x 4.88 x 4.55 x
EV / Revenue 4.74 x 5.83 x 5.46 x 5.85 x 5.89 x 6.1 x 5.69 x 5.16 x
EV / EBITDA 8.89 x 11.8 x 10.6 x 11 x 12.5 x 12.7 x 11.6 x 10.4 x
EV / FCF 12.4 x 15.9 x 13.9 x 14 x 14.5 x 17.3 x 13.9 x 12.5 x
FCF Yield 8.1% 6.29% 7.18% 7.14% 6.89% 5.77% 7.18% 7.99%
Price to Book -16.1 x 13.7 x 15.5 x 16.6 x 26.5 x 24.9 x 23.8 x 19.7 x
Nbr of stocks (in thousands) 1,478,821 1,765,474 1,767,880 1,767,880 1,765,537 1,770,647 - -
Reference price 2 88.54 107.2 135.4 161.6 155.0 159.6 159.6 159.6
Announcement Date 2/7/20 2/3/21 2/2/22 2/9/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 33,266 45,784 56,122 58,054 54,318 55,071 57,925 62,107
EBITDA 1 17,747 22,642 29,018 30,961 25,545 26,456 28,319 30,910
EBIT 1 15,730 21,976 28,215 30,183 24,793 25,505 27,441 30,143
Operating Margin 47.29% 48% 50.27% 51.99% 45.64% 46.31% 47.37% 48.53%
Earnings before Tax (EBT) 1 8,426 3,398 12,989 13,477 6,250 12,202 14,849 17,150
Net income 1 7,882 4,616 11,542 11,836 4,863 8,181 11,030 13,371
Net margin 23.69% 10.08% 20.57% 20.39% 8.95% 14.86% 19.04% 21.53%
EPS 2 5.280 2.720 6.450 6.630 2.720 5.227 6.737 8.035
Free Cash Flow 1 12,772 16,790 21,990 24,248 22,062 19,377 23,638 25,588
FCF margin 38.39% 36.67% 39.18% 41.77% 40.62% 35.18% 40.81% 41.2%
FCF Conversion (EBITDA) 71.97% 74.15% 75.78% 78.32% 86.37% 73.24% 83.47% 82.78%
FCF Conversion (Net income) 162.04% 363.73% 190.52% 204.87% 453.67% 236.84% 214.32% 191.38%
Dividend per Share 2 4.390 4.840 5.310 5.710 5.990 6.191 6.492 6.781
Announcement Date 2/7/20 2/3/21 2/2/22 2/9/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 14,342 14,886 13,538 14,583 14,812 15,121 12,225 13,865 13,927 14,301 12,310 14,031 14,181 14,707 13,254
EBITDA 1 7,559 7,506 7,156 7,643 8,090 8,072 5,682 6,710 6,706 6,447 5,444 7,100 6,877 7,049 -
EBIT 1 7,336 7,333 6,958 7,440 7,909 7,876 5,503 6,520 6,510 6,260 2,798 6,883 6,685 6,804 6,659
Operating Margin 51.15% 49.26% 51.4% 51.02% 53.4% 52.09% 45.01% 47.02% 46.74% 43.77% 22.73% 49.06% 47.14% 46.26% 50.24%
Earnings before Tax (EBT) 1 - - - - - - 475 2,610 1,953 1,212 1,755 3,781 3,532 3,979 -
Net income 1 3,179 4,044 4,490 924 3,949 2,473 239 2,024 1,778 822 1,369 2,145 1,932 2,084 1,115
Net margin 22.17% 27.17% 33.17% 6.34% 26.66% 16.35% 1.96% 14.6% 12.77% 5.75% 11.12% 15.29% 13.63% 14.17% 8.41%
EPS 2 1.780 2.260 2.510 0.5100 2.210 1.380 0.1300 1.140 1.000 0.4600 0.7700 1.572 1.330 1.392 0.6200
Dividend per Share 2 1.300 1.410 1.410 1.410 1.410 1.480 1.480 1.480 1.480 1.550 1.546 1.546 1.546 1.546 1.605
Announcement Date 10/29/21 2/2/22 4/29/22 7/29/22 10/28/22 2/9/23 4/27/23 7/27/23 10/27/23 2/2/24 4/26/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 26,804 77,607 66,854 54,042 46,571 53,102 46,703 37,643
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.51 x 3.428 x 2.304 x 1.745 x 1.823 x 2.007 x 1.649 x 1.218 x
Free Cash Flow 1 12,772 16,790 21,990 24,248 22,062 19,377 23,638 25,588
ROE (net income / shareholders' equity) -160% 188% 159% 151% 143% 162% 157% 171%
ROA (Net income/ Total Assets) 10.6% 3.85% 15.3% 17.2% 14.5% 11.6% 11.3% 13.5%
Assets 1 74,234 119,840 75,543 68,651 33,641 70,344 97,902 98,729
Book Value Per Share 2 -5.510 7.830 8.710 9.740 5.840 6.420 6.710 8.090
Cash Flow per Share 2 8.980 10.50 12.80 14.00 12.90 15.40 15.60 13.90
Capex 1 552 798 787 695 777 821 850 878
Capex / Sales 1.66% 1.74% 1.4% 1.2% 1.43% 1.49% 1.47% 1.41%
Announcement Date 2/7/20 2/3/21 2/2/22 2/9/23 2/2/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
159.6 USD
Average target price
182.6 USD
Spread / Average Target
+14.43%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
PFIZER, INC. Stock Pfizer, Inc.
-10.94% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. 0QCV Stock
  5. Financials AbbVie Inc.